Klaus Wielckens

1.8k total citations
51 papers, 1.4k citations indexed

About

Klaus Wielckens is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Klaus Wielckens has authored 51 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 17 papers in Oncology and 11 papers in Immunology. Recurrent topics in Klaus Wielckens's work include PARP inhibition in cancer therapy (15 papers), Toxin Mechanisms and Immunotoxins (7 papers) and Biochemical and Molecular Research (5 papers). Klaus Wielckens is often cited by papers focused on PARP inhibition in cancer therapy (15 papers), Toxin Mechanisms and Immunotoxins (7 papers) and Biochemical and Molecular Research (5 papers). Klaus Wielckens collaborates with scholars based in Germany, United States and Austria. Klaus Wielckens's co-authors include Helmuth Hilz, Peter Adamietz, Roman Pfister, Edward George, Reinhard Bredehorst, R Bredehorst, Erland Erdmann, Markus Scholz, Gebhart Malchau and C. A. Schneider and has published in prestigious journals such as Journal of Biological Chemistry, Analytical Biochemistry and Biochemical Journal.

In The Last Decade

Klaus Wielckens

50 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Klaus Wielckens Germany 21 702 560 239 214 164 51 1.4k
Bart Jessen United States 19 534 0.8× 476 0.8× 222 0.9× 108 0.5× 79 0.5× 46 1.4k
Sarvajit Chakravarty United States 22 773 1.1× 381 0.7× 166 0.7× 97 0.5× 24 0.1× 39 1.6k
Jianlin Qiao China 20 612 0.9× 402 0.7× 371 1.6× 171 0.8× 24 0.1× 108 1.6k
Johanna Ungerstedt Sweden 20 855 1.2× 206 0.4× 255 1.1× 48 0.2× 41 0.3× 40 1.4k
C. Rancoule France 22 687 1.0× 312 0.6× 108 0.5× 116 0.5× 39 0.2× 77 1.7k
Weigang Fang China 28 1.1k 1.6× 433 0.8× 139 0.6× 44 0.2× 384 2.3× 80 2.1k
Uma Yasothan United States 22 608 0.9× 433 0.8× 287 1.2× 55 0.3× 14 0.1× 30 1.4k
Michele Cea Italy 26 1.0k 1.5× 941 1.7× 290 1.2× 48 0.2× 331 2.0× 94 2.5k
Iraide Alloza Spain 19 396 0.6× 162 0.3× 532 2.2× 153 0.7× 20 0.1× 38 1.3k
Min Zheng China 21 723 1.0× 345 0.6× 189 0.8× 73 0.3× 26 0.2× 41 1.4k

Countries citing papers authored by Klaus Wielckens

Since Specialization
Citations

This map shows the geographic impact of Klaus Wielckens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Wielckens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Wielckens more than expected).

Fields of papers citing papers by Klaus Wielckens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Wielckens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Wielckens. The network helps show where Klaus Wielckens may publish in the future.

Co-authorship network of co-authors of Klaus Wielckens

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Wielckens. A scholar is included among the top collaborators of Klaus Wielckens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Wielckens. Klaus Wielckens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Johannis, Wibke, et al.. (2013). Anti-glycolipid antibodies in patients with neuropathy: A diagnostic assessment. Journal of Clinical Neuroscience. 21(3). 488–492. 4 indexed citations
2.
Johannis, Wibke, et al.. (2011). Ma2 antibodies: an evaluation of commercially available detection methods.. PubMed. 57(5-6). 321–6. 6 indexed citations
3.
Klatt, Andreas R., et al.. (2009). Discoidin domain receptor 2 mediates the collagen II‐dependent release of interleukin‐6 in primary human chondrocytes. The Journal of Pathology. 218(2). 241–247. 38 indexed citations
4.
Pfister, Roman, et al.. (2009). The relationship and prognostic impact of low-T3 syndrome and NT-pro-BNP in cardiovascular patients. International Journal of Cardiology. 144(2). 187–190. 22 indexed citations
5.
Müller‐Ehmsen, Jochen, Daniela A. Braun, Thomas Schneider, et al.. (2008). Decreased number of circulating progenitor cells in obesity: beneficial effects of weight reduction. European Heart Journal. 29(12). 1560–1568. 97 indexed citations
6.
Hornig‐Do, Hue‐Tran, Matthias Schauen, Trish Dinh, et al.. (2007). Impaired mitochondrial Ca2+ homeostasis in respiratory chain-deficient cells but efficient compensation of energetic disadvantage by enhanced anaerobic glycolysis due to low ATP steady state levels. Experimental Cell Research. 313(14). 3076–3089. 50 indexed citations
7.
Klatt, Andreas R., et al.. (2007). RNAi in primary human chondrocytes: Efficiencies, kinetics, and non-specific effects of siRNA-mediated gene suppression. Biologicals. 35(4). 321–328. 13 indexed citations
8.
Aleksic, M., et al.. (2005). Comparison of the Prevalence of APC-resistance in Vascular Patients and in a Normal Population Cohort in Western Germany. European Journal of Vascular and Endovascular Surgery. 30(2). 160–163. 8 indexed citations
9.
Pfister, Roman, Markus Scholz, Klaus Wielckens, Erland Erdmann, & C. A. Schneider. (2004). Use of NT-proBNP in Routine Testing and Comparison to BNP. European Journal of Heart Failure. 6(3). 289–293. 133 indexed citations
10.
Wielckens, Klaus, et al.. (2002). FOXD4a and FOXD4b, two new winged helix transcription factors, are expressed in human leukemia cell lines. Gene. 294(1-2). 131–140. 16 indexed citations
11.
Wielckens, Klaus, et al.. (2000). Apolipoprotein B-100: employing the electrochemiluminescence technology of the Elecsys systems for the detection of the point mutation Arg(3500)Gln.. PubMed. 46(1-2). 41–7. 3 indexed citations
12.
Suijlen, Jeroen D.E. van, B. G. Blijenberg, Jörg Hofmann, et al.. (2000). Multicentre evaluation of the Boehringer Mannheim/Hitachi 917 analysis system. Journal of Analytical Methods in Chemistry. 22(3). 65–81. 4 indexed citations
13.
Geisel, Jürgen, et al.. (1998). Mutation Analysis of Exon 3 of the LDL Receptor Gene in Patients with Severe Hypercholesterolemia. Clinical Chemistry and Laboratory Medicine (CCLM). 36(5). 279–282. 1 indexed citations
14.
Krohn, Karsten, et al.. (1992). Synthesis and cytotoxic activity of C-glycosidic nicotinamide riboside analogs. Journal of Medicinal Chemistry. 35(3). 511–517. 76 indexed citations
15.
Wielckens, Klaus, et al.. (1989). Mechanisms of Glucocorticoid-Induced Growth Inhibition and Cell Lysis in Mouse Lymphoma Cells. Hämatologie und Bluttransfusion. 32. 226–232. 1 indexed citations
16.
Wielckens, Klaus, et al.. (1988). Glucocorticoid-Induced Lymphoma Cell Growth Inhibition: The Role of Leukotriene B4*. Endocrinology. 123(2). 991–1000. 18 indexed citations
17.
Dikomey, Ekkehard, et al.. (1987). Reduction of DNA-polymerase β Activity of CHO Cells by Single and Combined Heat Treatments. International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine. 52(5). 775–785. 26 indexed citations
18.
Bredehorst, Reinhard, et al.. (1983). Quantification without purification of blood and tissue adenosine by radioimmunoassay. Analytical Biochemistry. 135(1). 156–164. 16 indexed citations
19.
Wielckens, Klaus, R Bredehorst, Peter Adamietz, & Helmuth Hilz. (1982). Mono ADP-ribosylation and poly ADP-ribosylation of proteins in normal and malignant tissues. Advances in Enzyme Regulation. 20. 23–37. 15 indexed citations
20.
Wielckens, Klaus, et al.. (1980). ADP‐Ribosylation of Nuclear Proteins in Normal Lymphocytes and in Low‐Grade Malignant Non‐Hodgkin Lymphoma Cells. European Journal of Biochemistry. 104(1). 279–287. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bart Jessen Breakdown of academic impact, for papers by Sarvajit Chakravarty Breakdown of academic impact, for papers by Jianlin Qiao Breakdown of academic impact, for papers by Johanna Ungerstedt Breakdown of academic impact, for papers by C. Rancoule Breakdown of academic impact, for papers by Weigang Fang Breakdown of academic impact, for papers by Uma Yasothan Breakdown of academic impact, for papers by Michele Cea Breakdown of academic impact, for papers by Iraide Alloza Breakdown of academic impact, for papers by Min Zheng
Rankless by CCL
2026